1. Home
  2. |Insights
  3. |Critical Reporting And Labeling Requirements for Products Containing PFAS: What Companies Need to Know (and DO) Now!

Critical Reporting And Labeling Requirements for Products Containing PFAS: What Companies Need to Know (and DO) Now!

Webinar | 06.23.26, 12:00 PM EDT - 1:00 PM EDT

Because of recent changes to Federal and State law regulations, companies that manufacture, import, sell, or distribute products or equipment with components that contain certain “PFAS” materials face imminent and overlapping compliance obligations. This webinar will provide actionable information companies can use to determine whether they are impacted by these State and Federal requirements as well as practical advice for complying with these obligations. Topics that will be covered include the following:

  • Key features of the federal and state PFAS reporting requirements and the impact of recent legislative and regulatory developments
  • New labeling requirements for products containing PFAS;
  • State product bans and exemptions for currently unavoidable uses of PFAS; and
  • Practical approaches to compliance, and pitfalls to avoid.

 

CLE Credit
This program is pending CLE credit in CA, CO, IL, NY, and TX. Credit hours are estimated and subject to each state’s approval and credit rounding rules. We will apply to have this program accredited in other jurisdictions upon request. CLE credit is only available for attendance at the live webinar. CLE credit is not available for viewing this program on-demand.

For more information, please visit these areas: Environment and Natural Resources, Government Contracts , Life Sciences, Product Risk Management, Transportation, Technology

Participants

Insights

Webinar | 12.10.26

The Third-Party Perspective: Protecting Payors’ Interests in Antitrust Investigations

The Trump administration has sharpened its focus on hospital systems as a key driver of rising health care costs, and the DOJ and FTC are actively patrolling for anticompetitive conduct and mergers that contribute to these rising costs. Managed care organizations are a critical source of evidence in these investigations and are likely to receive Civil Investigative Demands (CIDs), be contacted by agency staff, or may consider proactively engaging with antitrust authorities to address competitive concerns in their markets.